Background
==========

Gastric cancer is the second most common cancer in Eastern Asia \[[@b1-medscimonitbasicres-26-e920778]\]. In Japan, mortality from gastric cancer may be reduced due to screening, although the incidence remains high \[[@b2-medscimonitbasicres-26-e920778],[@b3-medscimonitbasicres-26-e920778]\]. A reduction in the incidence of gastric cancer has been reported in the Shanghai urban area \[[@b4-medscimonitbasicres-26-e920778]\]. However, mortality in this region has not decreased, resulting in a high rate of individuals with advanced gastric cancer \[[@b5-medscimonitbasicres-26-e920778]\]. The characteristics of advanced gastric cancer should be investigated to improve survival.

Glucose transporter-1 (GLUT-1) is a member of the major transporter superfamily \[[@b6-medscimonitbasicres-26-e920778]\] and regulates glucose distribution by controlling the direction of movement of glucose \[[@b7-medscimonitbasicres-26-e920778]\]. The transporter is expressed in numerous cell types, such as erythrocytes, brain cells, and muscle cells, at varying levels \[[@b8-medscimonitbasicres-26-e920778]\]. It is significant that for tissues depending on glucose for energy production that GLUT-1 is a highly expressed protein \[[@b9-medscimonitbasicres-26-e920778]\]. In addition, a variety of cancers, including lung cancer and colorectal carcinoma, overexpress GLUT-1 \[[@b10-medscimonitbasicres-26-e920778],[@b11-medscimonitbasicres-26-e920778]\].

GLUT-1 positivity in gastric cancer is not high among malignant tumors and is only 19\~29.5% in Japan \[[@b12-medscimonitbasicres-26-e920778],[@b13-medscimonitbasicres-26-e920778]\], 16.9\~43.0% in Korea \[[@b14-medscimonitbasicres-26-e920778]--[@b16-medscimonitbasicres-26-e920778]\], and 22.0\~50.0% in Germany \[[@b17-medscimonitbasicres-26-e920778],[@b18-medscimonitbasicres-26-e920778]\]. Depth of invasion, lymphatic permeation, venous invasion, lymph node metastasis, and hepatic metastasis were associated with s positive rate in Japan, where early gastric cancer is predominant among all gastric cancer cases \[[@b13-medscimonitbasicres-26-e920778]\]. The clinicopathological parameters associated with GLUT-1 expression in advanced gastric cancer in the Chinese population are still controversial. Therefore, this study aimed to explore the clinicopathological parameters and prognosis related to GLUT-1 in advanced gastric cancer.

Material and Methods
====================

Patients
--------

A total of 234 consecutive patients who did not undergo preoperative chemotherapy or radiotherapy between January 2008 and January 2014 at the Fifth People's Hospital of Shanghai were enrolled in this study. All of them had pathologically confirmed disease after gastrectomy and lymph node dissection. All advanced stage cases underwent radical gastrectomy and D2 dissection. Adjuvant chemotherapy has been employed according to NCCN clinical practice guidelines. Advanced gastric cancer patients underwent chemotherapy protocol including mFOLFOX and SOX. All enrolled patients had an over 5-years follow-up period and examinations at regular intervals. The local Research Ethics Commission approved this study.

The staging system used in of this study was the American Joint Committee on Cancer, 8^th^ edition. Histology was scored according to the World Health Organization (WHO) classification \[[@b19-medscimonitbasicres-26-e920778]\]. The characteristics of the patients are shown in [Table 1](#t1-medscimonitbasicres-26-e920778){ref-type="table"}.

Experimental procedures
-----------------------

Paraffin-embedded samples of tumors were sliced into 4 μm-thick specimens. After deparaffinization and hydration, the slides were treated with 3% H~2~O~2~ for 10 minutes at room temperature. We used 0.01 M sodium citrate buffer (pH 6.0) at 100°C for 1 minute for antigen retrieval. The slides were incubated with primary monoclonal GLUT-1 antibody (ab40084, Abcam, UK, 1: 100). EnVision detection systems (Peroxidase/DAB, Rabbit/Mouse, DAKO) were used for staining. After treatment with the kits, the sections were counterstained with Mayer's hematoxylin. Then, the specimens were dehydrated with gradient ethanol series and sealed with neutral balsam. For quality control, omission of the GLUT-1 antibody and use of isotype controls (ab18413, Abcam, UK) were performed.

The analyses were conducted by experienced pathologists blinded to the patients' clinical information. Positive tumor cells were identified by staining of the cell membrane ([Figure 1](#f1-medscimonitbasicres-26-e920778){ref-type="fig"}). The GLUT-1 expression level was evaluated by semiquantitative assessment \[[@b20-medscimonitbasicres-26-e920778],[@b21-medscimonitbasicres-26-e920778]\]. The scoring system criteria were as follows: 0 as \<1% positive tumor cells; 1 as 1\~30% positive tumor cells; and 2 as \>30% positive tumor cells.

Statistical analysis
--------------------

Continuous variables are expressed as mean values with standard deviation or range. Chi-squared test or Fisher's exact test was performed to determine the relationship between GLUT-1 expression and clinicopathological parameters such as gender and tumor localization. Age and tumor diameter of the GLUT-1-positive and GLUT-1-negative groups were compared with the Mann-Whitney U test. Multivariate analyses of GLUT-1 expression and potentially significant factors (*P*\<0.10) were performed with logistic regression analysis, which was verified by stepwise regression of all clinicopathological parameters. The 132 patients with stage M0 advanced gastric cancer who had undergone radical gastrectomy (dissected lymph nodes ≥20, R0 resection) were included in the survival analysis with the Kaplan-Meier method and log-rank test. Cox regression multivariate analysis included the clinicopathological parameters for survival analysis. *P*\<0.05 was considered to be statistically significant. SPSS software, version 16.0, was used for all statistical analyses.

Results
=======

In these gastric cancer patients, the overall positive rate of GLUT-1 expression was 57.69% (135 out of 234 patients). The relationship between GLUT-1 and clinicopathological parameters is shown in [Table 1](#t1-medscimonitbasicres-26-e920778){ref-type="table"}. Tumor diameter, localization, M stage, and histology/Lauren type were associated with GLUT-1 expression in advanced gastric cancer ([Table 2](#t2-medscimonitbasicres-26-e920778){ref-type="table"}). Tumor diameter, M stage, and Lauren type were also independent factors ([Table 3](#t3-medscimonitbasicres-26-e920778){ref-type="table"}).

The median follow-up period was 48.45 months. The mean survival time of GLUT-1-positive patients with stage M0 advanced gastric cancer who had undergone radical gastrectomy was shorter than that of GLUT-1-negative patients (61.26±6.12 versus 80.88±7.38, *P*=0.044) ([Figure 2](#f2-medscimonitbasicres-26-e920778){ref-type="fig"}). The hepatic metastasis hazard curve of GLUT-1-positive patients was higher than that of negative patients ([Figure 3](#f3-medscimonitbasicres-26-e920778){ref-type="fig"}). Age, tumor diameter, pT, pN, GLUT-1, and adjuvant chemotherapy were related to survival time in our univariate analysis ([Table 4](#t4-medscimonitbasicres-26-e920778){ref-type="table"}). GLUT-1 was an independent prognosis factor in locally advanced gastric cancer undergone radical gastrectomy (hazard ratio \[HR\] 1.769, *P*=0.046) ([Table 5](#t5-medscimonitbasicres-26-e920778){ref-type="table"}).

The mean survival time of the adjuvant chemotherapy group was significantly better than the no adjuvant chemotherapy group in the GLUT-1-positive and negative groups ([Figure 4](#f4-medscimonitbasicres-26-e920778){ref-type="fig"}). The mean survival time for patients in the adjuvant chemotherapy and no adjuvant chemotherapy groups in the GLUT-1-positive group was 71.10±6.88 and 24.65±8.69 months, respectively; whereas in the GLUT-1-negative the mean survival time was 87.48±7.99 and 49.39±11.71 months, respectively.

Discussion
==========

Reprogramming energy metabolism is one of the canonical hallmarks of cancer \[[@b22-medscimonitbasicres-26-e920778]\]. Glucose metabolism is not only essential for human survival but also associated with carcinogenesis \[[@b23-medscimonitbasicres-26-e920778]\]. GLUT-1 is a typical transporter involved in metabolism and has been further elucidated with xyIE reporter analyses \[[@b24-medscimonitbasicres-26-e920778]\]. Gastric cancer and other malignant tumors have been found to be related to GLUT-1 \[[@b11-medscimonitbasicres-26-e920778],[@b13-medscimonitbasicres-26-e920778],[@b25-medscimonitbasicres-26-e920778]--[@b28-medscimonitbasicres-26-e920778]\]. The Warburg phenotype, which is GLUT-1 positive, is the most common phenotype in triple-negative breast cancer and corresponds to a poor prognosis \[[@b29-medscimonitbasicres-26-e920778]\]. The GLUT-1 positive rate of other digestive tract neoplasms, such as colorectal and esophageal carcinoma, is higher (90\~100%) \[[@b11-medscimonitbasicres-26-e920778],[@b30-medscimonitbasicres-26-e920778]\]. However, there have been discrepancies among several studies on GLUT-1 expression in gastric cancer. Therefore, we analyzed its expression in various situation in our study.

In our study, the positive rate of GLUT-1 expression in gastric cancer samples was similar to that reported in previous studies \[[@b12-medscimonitbasicres-26-e920778]--[@b16-medscimonitbasicres-26-e920778],[@b31-medscimonitbasicres-26-e920778]--[@b38-medscimonitbasicres-26-e920778]\]. Moreover, the positive rate in the advanced stage group was significantly higher than that in the early stage group. The difference in the ratio of advanced to early stage cancer patients among studies may result in a higher positive rate found in Chinese studies, including ours, than found in studies from other East Asian countries \[[@b12-medscimonitbasicres-26-e920778]--[@b16-medscimonitbasicres-26-e920778],[@b31-medscimonitbasicres-26-e920778]--[@b38-medscimonitbasicres-26-e920778]\]. The ratio in our study was significantly higher than that of other large case studies \[[@b13-medscimonitbasicres-26-e920778]\]. The differences in the epidemiological characteristics are likely caused by the varying strategies for diagnosing and treating gastric cancer. For example, an advanced screening system for gastric cancer in Japan may lead to a lower proportion of individuals with advanced gastric cancer than found in other East Asian countries \[[@b2-medscimonitbasicres-26-e920778],[@b3-medscimonitbasicres-26-e920778]\].

Tumor diameter and pT stage were independent factors associated with GLUT-1 expression in all gastric cancer cases, and they were positively correlated with each other. The growth of gastric lesions in perpendicular directions determined the independence of these variables \[[@b39-medscimonitbasicres-26-e920778]\]. Tumor diameter was also an independent factor in advanced stage gastric cancer, which suggested that GLUT-1 expression was associated with further tumor enlargement.

Korean studies have suggested that the intestinal type of gastric cancer is related to GLUT-1 \[[@b14-medscimonitbasicres-26-e920778],[@b16-medscimonitbasicres-26-e920778],[@b40-medscimonitbasicres-26-e920778]\]. Our study also obtained a similar result: multivariate analysis of overall or advanced stage gastric cancer revealed that the positive rate of GLUT-1 in intestinal gastric cancer was higher than that in the diffuse type. Lauren proposed his classification of gastric carcinoma in 1965 \[[@b41-medscimonitbasicres-26-e920778]\]. This histological classification is simplified, accessible, and reproducible to the benefit of research \[[@b42-medscimonitbasicres-26-e920778]\]. Both the Lauren classification and the WHO classification have been commonly used in gastric cancer studies, which can be correlated to each other \[[@b42-medscimonitbasicres-26-e920778]\]. The mucinous and signet-ring cell types in the WHO classification are mostly categorized as diffuse type in the Lauren classification. The positive rate of GLUT-1 expression in the 2 types was lower than that in the differentiated type \[[@b13-medscimonitbasicres-26-e920778],[@b31-medscimonitbasicres-26-e920778]\]. Therefore, the lower rate in the diffuse type was probably the result of the characteristics of mucinous and signet-ring cell gastric cancer. GLUT-1 might be a potential metabolic biomarker for the intestinal type in advanced gastric cancer.

There have been different results from previous Chinese studies on the relationship between GLUT-1 expression and differentiated type in gastric cancer \[[@b31-medscimonitbasicres-26-e920778]--[@b35-medscimonitbasicres-26-e920778]\]. Wei et al. found that the GLUT-1 positive rate in well-differentiated types of gastric cancers was higher than that in moderately and poorly differentiated types \[[@b31-medscimonitbasicres-26-e920778]\]. Nevertheless, other researchers presented distinct results that showed the rate of poorly differentiated and undifferentiated type was higher \[[@b33-medscimonitbasicres-26-e920778]--[@b35-medscimonitbasicres-26-e920778]\]. Our study demonstrated that GLUT-1 expression was positively correlated with differentiation grade. The positive rate of moderately differentiated type was the highest of all the types, which was in line with the results reported by Yu et al. \[[@b32-medscimonitbasicres-26-e920778]\]. Such contradictory results suggest that GLUT-1 is probably a molecular factor that is not dependent on differentiation.

Kawamura et al. found that GLUT-1 expression was associated with poor survival in gastric cancer patients using multivariate analyses \[[@b13-medscimonitbasicres-26-e920778]\]. Jung et al. in Korea also affirmed that GLUT-1-positive gastric cancer patients had a shorter mean survival time \[[@b16-medscimonitbasicres-26-e920778]\]. Nevertheless, studies in China have not clearly shown that GLUT-1 expression is related to poor prognosis \[[@b31-medscimonitbasicres-26-e920778],[@b35-medscimonitbasicres-26-e920778]\]. This inconsistency may be associated with differences in the epidemiological characteristics of gastric cancer between patients in China and those in other East Asian countries. Patients with advanced stage gastric cancer are predominant in China due to the country's strategy on diagnosing and treating cancer. Moreover, the development of multi-disciplinary treatments with new drugs, devices, and techniques has improved the survival of advanced gastric cancer \[[@b43-medscimonitbasicres-26-e920778]\]. This study only showed that GLUT-1 positivity was associated with poor survival in stage M0 advanced gastric cancer patients who had undergone radical gastrectomy. Therefore, the epidemiological characteristics limited the application of our work in overall stages of gastric cancer. The hepatic metastasis hazard curve of GLUT-1-positive stage M0 advanced gastric cancer after radical gastrectomy was higher than that of the GLUT-1-negative group, and GLUT-1 expression was associated with the intestinal type of advanced gastric cancer.

The chemotherapy regime 5-fluorouracil (5-FU) has been shown to affect GLUT-1 on gastric cancer cell *in vitro,* which indicates that GLUT-1 may be partly associated with responses to 5-FU chemotherapy in gastric cancer \[[@b44-medscimonitbasicres-26-e920778]\]. Lu et al. suggested that GLUT-1 may be a marker for gastric cancer sensitivity to ascorbate in chemotherapy with *in vitro* and *in vivo* experiments \[[@b45-medscimonitbasicres-26-e920778]\]. Our work indicated that GLUT-1-positive patients might be subject to benefit from chemotherapy based on clinical data.

Although our work suggested that GLUT-1 might be associated with hepatic metastasis from gastric cancer and chemotherapy responses, there were a few limitations to our study, including the study was a small single center retrospective study and advanced gastric cancer was the predominantly patient diagnosis (especially pT4 staging). The relationship between GLUT-1, hepatic metastasis and chemotherapy, and mechanism of chemotherapy responses related to GLUT-1 should be further investigated.

Conclusions
===========

GLUT-1 expression in advanced stage gastric cancer was significantly higher than that in early stage gastric cancer. Tumor size and Lauren type independently affected GLUT-1 expression in advanced gastric cancer. GLUT-1 was not only related to poor prognosis but also predicted to be a metabolic biomarker for the Lauren classification in locally advanced gastric cancer.
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###### 

The relation between GLUT-1 expression and clinicopathological parameters in 234 gastric cancer cases.

  Clinicopathological parameters   GLUT-1 expression   *P*-value     
  -------------------------------- ------------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------
  Gender                                                             0.086
   Male                            63 (63.6%)          100 (74.1%)   
   Female                          36 (36.4%)          35 (25.9%)    
  Age (year)                       63±13               65±11         0.219[a](#tfn1-medscimonitbasicres-26-e920778){ref-type="table-fn"}
  Tumor diameter(cm)               4.31±2.30           5.24±2.60     0.002[a](#tfn1-medscimonitbasicres-26-e920778){ref-type="table-fn"},[\*](#tfn4-medscimonitbasicres-26-e920778){ref-type="table-fn"}
  Tumor localization                                                 0.013[\*](#tfn4-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   Upper                           10 (10.1%)          34 (25.2%)    
   Middle                          18 (18.2%)          18 (13.3%)    
   Lower                           71 (71.7%)          83 (61.5%)    
  pT                                                                 0.088[b](#tfn2-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   T1 (T1a, T1b)                   25 (25.3%)          19 (14.1%)    
   T2                              14 (14.1%)          14 (10.4%)    
   T3                              1 (1.0%)            3 (2.2%)      
   T4 (T4a, T4b)                   59 (59.6%)          99 (73.3%)    
  pN                                                                 0.936
   N0                              29 (29.3%)          41 (30.4%)    
   N1                              15 (15.2%)          24 (17.8%)    
   N2                              23 (23.2%)          30 (22.2%)    
   N3 (N3a, N3b)                   32 (32.3%)          40 (29.6%)    
  M                                                                  0.009[b](#tfn2-medscimonitbasicres-26-e920778){ref-type="table-fn"},[\*](#tfn4-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   M0                              97 (98.0%)          120 (88.9%)   
   M1                              2 (2.0%)            15 (11.1%)    
  TNM stage                                                          0.133[b](#tfn2-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   IA, IB                          25 (25.3%)          25 (18.5%)    
   IIA, IIB                        18 (18.2%)          24 (17.8%)    
   IIIA, IIIB, IIIC                54 (54.5%)          75 (55.6%)    
   IV                              2 (2.0%)            11 (8.1%)     
  Clinical stage                                                     0.031[\*](#tfn4-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   Early                           25 (25.3%)          19 (14.1%)    
   Advanced                        74 (74.7%)          116 (85.9%)   
  Histology                                                          \<0.001[b](#tfn2-medscimonitbasicres-26-e920778){ref-type="table-fn"},[\*](#tfn4-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   Well differentiated             18 (18.2%)          32 (23.7%)    \<0.001[c](#tfn3-medscimonitbasicres-26-e920778){ref-type="table-fn"},[\*](#tfn4-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   Moderately differentiated       22 (22.2%)          60 (44.4%)    
   Poorly differentiated           49 (49.5%)          36 (26.7%)    
   Signet-ring cell                9 (9.1%)            5 (3.7%)      
   Mucinous                        1 (1.0%)            2 (1.5%)      
  Lauren type                                                        \<0.001[\*](#tfn4-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   Intestinal                      40 (40.4%)          92 (68.1%)    
   Diffuse                         59 (59.6%)          43 (31.9%)    
  Venous invasion                                                    0.061
   Positive                        62 (62.6%)          100 (74.1%)   
   Negative                        37 (37.4%)          35 (25.9%)    
  Lymphatic invasion                                                 0.919
   Positive                        71 (71.7%)          96 (71.1%)    
   Negative                        28 (28.3%)          39 (28.9%)    
  Perineural invasion                                                0.047[\*](#tfn4-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   Positive                        51 (51.5%)          87 (64.4%)    
   Negative                        48 (48.5%)          48 (35.6%)    

Mann-Whitney U test;

Fisher's exact test;

Comparison of different grade in adenocarcinoma.

*P*\<0.05.

GLUT-1 -- glucose transporter-1.

###### 

The relation between GLUT-1 expression and clinicopathological parameters in 190 advanced gastric cancer cases.

  Clinicopathological parameters   GLUT-1 expression   *P-*value     
  -------------------------------- ------------------- ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gender                                                             0.191
   Male                            49 (66.2%)          87 (75.0%)    
   Female                          25 (33.8%)          29 (25.0%)    
  Age (year)                       63±14               66±11         0.099[a](#tfn6-medscimonitbasicres-26-e920778){ref-type="table-fn"}
  Tumor diameter (cm)              4.78±2.35           5.68±2.48     0.007[a](#tfn6-medscimonitbasicres-26-e920778){ref-type="table-fn"},[\*](#tfn9-medscimonitbasicres-26-e920778){ref-type="table-fn"}
  Tumor localization                                                 0.039[\*](#tfn9-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   Upper                           9 (12.2%)           32 (27.6%)    
   Middle                          14 (18.9%)          16 (13.8%)    
   Lower                           51 (68.9%)          68 (58.6%)    
  pT                                                                 0.382[b](#tfn7-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   T2                              14 (18.9%)          14 (12.1%)    
   T3                              1 (1.4%)            3 (2.6%)      
   T4 (T4a, T4b)                   59 (79.7%)          99 (85.3%)    
  pN                                                                 0.328
   N0                              9 (12.2%)           26 (22.4%)    
   N1                              13 (17.5%)          21 (18.1%)    
   N2                              21 (28.4%)          29 (25.0%)    
   N3 (N3a, N3b)                   31 (41.9%)          40 (34.5%)    
  M                                                                  0.012[b](#tfn7-medscimonitbasicres-26-e920778){ref-type="table-fn"},[\*](#tfn9-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   M0                              72 (97.3%)          101 (87.1%)   
   M1                              2 (2.7%)            15 (12.9%)    
  TNM stage                                                          0.233[b](#tfn7-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   IB                              3 (4.0%)            7 (6.0%)      
   IIA, IIB                        15 (20.3%)          23 (19.8%)    
   IIIA, IIIB, IIIC                54 (73.0%)          75 (64.7%)    
   IV                              2 (2.7%)            11 (9.5%)     
  Histology                                                          \<0.001[b](#tfn7-medscimonitbasicres-26-e920778){ref-type="table-fn"},[\*](#tfn9-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   Well differentiated             8 (10.8%)           20 (17.3%)    \<0.001[b](#tfn7-medscimonitbasicres-26-e920778){ref-type="table-fn"},[c](#tfn8-medscimonitbasicres-26-e920778){ref-type="table-fn"},[\*](#tfn9-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   Moderately differentiated       16 (21.6%)          57 (49.1%)    
   Poorly differentiated           43 (58.1%)          34 (29.3%)    
   Signet-ring cell                6 (8.1%)            3 (2.6%)      
   Mucinous                        1 (1.4%)            2 (1.7%)      
  Lauren type                                                        \<0.001[\*](#tfn9-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   Intestinal                      24 (32.4%)          77 (66.4%)    
   Diffuse                         50 (67.6%)          39 (33.6%)    
  Venous invasion                                                    0.085
   Positive                        55 (74.3%)          98 (84.5%)    
   Negative                        19 (25.7%)          18 (15.5%)    
  Lymphatic invasion                                                 0.100
   Positive                        65 (87.8%)          91 (78.4%)    
   Negative                        9 (12.2%)           25 (21.6%)    
  Perineural invasion                                                0.265
   Positive                        50 (67.6%)          87 (75.0%)    
   Negative                        24 (32.4%)          29 (25.0%)    

Mann-Whitney U test;

Fisher's exact test;

Comparison of different grade in adenocarcinoma.

*P*\<0.05.

GLUT-1 -- glucose transporter-1.

###### 

The logistic regression analysis of GLUT-1 expression with clinicopathological parameters in 190 advanced gastric cancer cases.

  Parameters                              Regression coefficient (95% CI)   OR (95% CI)             *P*-value
  --------------------------------------- --------------------------------- ----------------------- -------------------------------------------------------------------------
  Gender                                  −0.310 (−0.709\~0.089)            0.734 (0.336\~1.602)    0.437
  Age                                     0.012 (−0.003\~0.027)             1.012 (0.982\~1.043)    0.453
  Tumor diameter                          0.198 (0.120\~0.276)              1.220 (1.047\~1.420)    0.011[\*](#tfn11-medscimonitbasicres-26-e920778){ref-type="table-fn"}
  Tumor localization                      −0.272 (−0.494\~−0.050)           0.762 (0.493\~1.177)    0.221
  pT                                      0.306 (0.051\~0.561)              1.358 (0.825\~2.236)    0.229
  pN                                      −0.369 (−0.621\~−0.117)           0.691 (0.422\~1.133)    0.143
  M                                       2.168 (1.280\~3.056)              8.744 (1.535\~49.819)   0.015[\*](#tfn11-medscimonitbasicres-26-e920778){ref-type="table-fn"}
  Lauren type (intestinal *=*. diffuse)   1.338 (0.980\~1.696)              3.810 (1.888\~7.687)    \<0.001[\*](#tfn11-medscimonitbasicres-26-e920778){ref-type="table-fn"}
  Venous invasion                         −0.682 (−1.230\~−0.134)           0.506 (0.173\~1.481)    0.214
  Lymphatic invasion                      0.356 (−0.358\~1.070)             1.427 (0.352\~5.790)    0.618
  Perineural invasion                     −0.079 (−0.555\~0.397)            0.924 (0.364\~2.349)    0.869

*P*\<0.05.

OR -- odds ratio; CI -- confidence interval; GLUT-1 -- glucose transporter-1.

###### 

Kaplan-Meier survival analysis in stage M0 advanced gastric cancer after radical gastrectomy (dissected lymph nodes ≥20, R0 resection).

  Parameters              Mean survival time, months (95%CI)   *P*-value
  ----------------------- ------------------------------------ -------------------------------------------------------------------------
  Gender                                                       0.793
   Male                   68.39 (57.516\~79.265)               
   Female                 67.96 (50.524\~85.393)               
  Age (year)                                                   \<0.001[\*](#tfn13-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   \<65                   91.08 (78.064\~104.100)              
   ≥65                    51.37 (39.539\~63.202)               
  Tumor diameter (cm)                                          0.003[\*](#tfn13-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   \<5                    81.28 (68.810\~93.754)               
   ≥5                     56.26 (43.277\~69.233)               
  Tumor localization                                           0.073
   Upper                  36.67 (21.558\~51.772)               
   Middle                 74.96 (52.284\~97.628)               
   Lower                  72.83 (61.413\~84.251)               
  pT                                                           0.006[\*](#tfn13-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   T2                     101.73 (84.760\~118.691)             
   T3\~4 (T4a, T4b)       62.65 (52.27\~73.02)                 
  pN                                                           0.002[\*](#tfn13-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   N0                     77.86 (59.137\~96.587)               
   N1                     99.64 (80.68\~118.61)                
   N2                     63.72 (47.12\~80.33)                 
   N3 (N3a, N3b)          43.59 (30.21\~59.96)                 
  Lauren type                                                  0.763
   Intestinal             69.39 (56.784\~81.993)               
   Diffuse                68.74 (54.751\~82.735)               
  Venous invasion                                              0.059
   Positive               64.72 (54.178\~75.261)               
   Negative               69.86 (55.660\~84.068)               
  Lymphatic invasion                                           0.363
   Positive               74.77 (56.08\~93.45)                 
   Negative               67.23 (56.46\~78.00)                 
  Perineural invasion                                          0.052
   Positive               63.77 (52.674\~74.857)               
   Negative               69.07 (56.085\~82.064)               
  GLUT-1                                                       0.044[\*](#tfn13-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   Positive               61.26 (49.256\~73.256)               
   Negative               80.88 (66.418\~95.348)               
  Adjuvant chemotherapy                                        \<0.001[\*](#tfn13-medscimonitbasicres-26-e920778){ref-type="table-fn"}
   Yes                    78.16 (67.763\~88.563)               
   No                     35.74 (19.779\~51.692)               

*P*\<0.05.

CI -- confidence interval; GLUT-1 -- glucose transporter-1.

###### 

Cox regression multivariate analysis in stage M0 advanced gastric cancer after radical gastrectomy (dissected lymph nodes ≥20, R0 resection).

  Parameters              HR (95% CI)            *P*-value
  ----------------------- ---------------------- -------------------------------------------------------------------------
  Gender                  1.065 (0.605\~1.876)   0.826
  Age                     1.043 (1.016\~1.071)   0.001[\*](#tfn15-medscimonitbasicres-26-e920778){ref-type="table-fn"}
  Tumor diameter          1.094 (0.994\~1.205)   0.067
  Tumor localization      0.641 (0.452\~0.910)   0.013[\*](#tfn15-medscimonitbasicres-26-e920778){ref-type="table-fn"}
  pT                      1.408 (0.901\~2.201)   0.133
  pN                      2.840 (1.755\~4.597)   \<0.001[\*](#tfn15-medscimonitbasicres-26-e920778){ref-type="table-fn"}
  Lauren type             0.778 (0.467\~1.296)   0.335
  Venous invasion         0.644 (0.226\~1.839)   0.411
  Lymphatic invasion      0.171 (0.051\~0.576)   0.004[\*](#tfn15-medscimonitbasicres-26-e920778){ref-type="table-fn"}
  Perineural invasion     1.404 (0.646\~3.052)   0.392
  GLUT-1                  1.769 (1.010\~3.096)   0.046[\*](#tfn15-medscimonitbasicres-26-e920778){ref-type="table-fn"}
  Adjuvant chemotherapy   0.468 (0.253\~0.866)   0.016[\*](#tfn15-medscimonitbasicres-26-e920778){ref-type="table-fn"}

*P*\<0.05.

GLUT-1 -- glucose transporter-1.
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